Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alex Stephens

Showing results (41-50 of 50) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 50 results.
European Urology Focus|August 7, 2025
Long-term Cancer Control Outcomes After Robot-assisted Radical Prostatectomy in Pathologically Non-organ-confined High-risk Prostate Cancer: 20-year Report from a Single Tertiary Referral CenterAlessandro Bertini, Alex Stephens, Alessio Finocchiaro, et al.
The Prostate|October 28, 2024
Association of race with incidence, characteristics, and mortality from incidental prostate cancer: Analysis of two North American contemporary cohortsMarco Finati, Chase Morrison, Alex Stephens, et al.
Cancer|May 28, 2024
Race has no impact on prostate cancer-specific mortality, when comparing patients with similar risk of other-cause mortality: An analysis of a population-based cohortShane A Tinsley, Marco Finati, Alex Stephens, et al.
International Urology and Nephrology|November 11, 2024
Surgery versus radiation for clinically positive nodal prostate cancer in an other cause mortality risk weighted cohortShane A Tinsley, Alex Stephens, Marco Finati, et al.
World Journal of Urology|October 22, 2025
Evaluating the learning curve for single-port radical prostatectomy: a multi-institutional cohort analysisAlessio Finocchiaro, Nicolò Buffi, Muhannad Aljoulani, et al.
Clinical Genitourinary Cancer|September 27, 2024
Survival Outcomes by Race Following Surgical Treatment for Upper Tract Urothelial CarcinomaJason Zappia, Courtney Yong, James Slaven, et al.
Cancers|July 12, 2025
Prognostic Impact of Adjuvant Immunotherapy in Patients with High-Risk Upper Tract Urothelial Cancer: Results from the ROBUUST 2.0 Collaborative GroupMaxwell Otiato, Farshad Sheybaee Moghaddam, Alireza Ghoreifi, et al.
World Journal of Urology|April 18, 2025
Combined neoadjuvant and adjuvant therapy versus adjuvant therapy in high-risk upper tract urothelial carcinoma: a propensity matched multicenter analysis (ROBUUST 2.0 International Collaborative Group)Ahmed Eraky, Reuben Ben-David, Gabriele Bignante, et al.
World Journal of Urology|September 2, 2025
Radical nephroureterectomy vs kidney sparing surgery for upper tract urothelial carcinoma in solitary kidney patients: a multi-institutional analysis of the ROBUUST 2.0 registryFrancesco Ditonno, Alessandro Veccia, Gabriele Bignante, et al.
Urology Practice|June 22, 2026
Metachronous contralateral recurrence in upper tract urothelial carcinoma: a multi-institutional competing-risks analysis from the ROBUUST 3.0 registryFrancesco Ditonno, Alessandro Veccia, Giacomo Musso, et al.
Pageof 5

Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
European Urology Focus|August 7, 2025
Long-term Cancer Control Outcomes After Robot-assisted Radical Prostatectomy in Pathologically Non-organ-confined High-risk Prostate Cancer: 20-year Report from a Single Tertiary Referral CenterAlessandro Bertini, Alex Stephens, Alessio Finocchiaro, et al.
The Prostate|October 28, 2024
Association of race with incidence, characteristics, and mortality from incidental prostate cancer: Analysis of two North American contemporary cohortsMarco Finati, Chase Morrison, Alex Stephens, et al.
Cancer|May 28, 2024
Race has no impact on prostate cancer-specific mortality, when comparing patients with similar risk of other-cause mortality: An analysis of a population-based cohortShane A Tinsley, Marco Finati, Alex Stephens, et al.
International Urology and Nephrology|November 11, 2024
Surgery versus radiation for clinically positive nodal prostate cancer in an other cause mortality risk weighted cohortShane A Tinsley, Alex Stephens, Marco Finati, et al.
World Journal of Urology|October 22, 2025
Evaluating the learning curve for single-port radical prostatectomy: a multi-institutional cohort analysisAlessio Finocchiaro, Nicolò Buffi, Muhannad Aljoulani, et al.
Clinical Genitourinary Cancer|September 27, 2024
Survival Outcomes by Race Following Surgical Treatment for Upper Tract Urothelial CarcinomaJason Zappia, Courtney Yong, James Slaven, et al.
Cancers|July 12, 2025
Prognostic Impact of Adjuvant Immunotherapy in Patients with High-Risk Upper Tract Urothelial Cancer: Results from the ROBUUST 2.0 Collaborative GroupMaxwell Otiato, Farshad Sheybaee Moghaddam, Alireza Ghoreifi, et al.
World Journal of Urology|April 18, 2025
Combined neoadjuvant and adjuvant therapy versus adjuvant therapy in high-risk upper tract urothelial carcinoma: a propensity matched multicenter analysis (ROBUUST 2.0 International Collaborative Group)Ahmed Eraky, Reuben Ben-David, Gabriele Bignante, et al.
World Journal of Urology|September 2, 2025
Radical nephroureterectomy vs kidney sparing surgery for upper tract urothelial carcinoma in solitary kidney patients: a multi-institutional analysis of the ROBUUST 2.0 registryFrancesco Ditonno, Alessandro Veccia, Gabriele Bignante, et al.
Urology Practice|June 22, 2026
Metachronous contralateral recurrence in upper tract urothelial carcinoma: a multi-institutional competing-risks analysis from the ROBUUST 3.0 registryFrancesco Ditonno, Alessandro Veccia, Giacomo Musso, et al.
Pageof 5